Skip to main content


Dana C. Matthews, MD

Dana C. Matthews, MD


On staff since March 1988

Children's Title: Director, Clinical Hematology; Chair, Blood Usage Committee

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

"Every time I walk into a clinic room to meet a new patient, I enjoy getting to know the patient and the parents, perhaps hearing a new language and learning something about what their life is like. I try hard to understand what they know, what they do not know, how I can best explain the diagnosis, and how we can work together most effectively to make decisions about diagnosis and treatment. I am profoundly fortunate to work with colleagues who are smart, warm and witty people as well as great clinicians. They care about our patients and about their colleagues on our team. Working together is stimulating, fun and gratifying."


JerraTonasket, WA08.01.13
We are VERY impressed with this impressive doctor! She knows what she's doing and we are confident with her skills. Highly Recommended!!!
RebeccaRichland, WA05.18.12
Dr. Matthews was warm, friendly and so helpful when she examined our failure-to-thrive baby. It's wonderful when a doctor who really knows their stuff also knows how to care for people. Thank you, Dr. Matthews.
MaureenBristow, VA12.14.11
Dr. Dana Matthews and her team are outstanding!!! We have been extremely confident in her ability to treat our son.
LynnSeattle, WA12.01.10
Dana is an amazing doctor that really has a handle on dealing not only with the patient but also with the families. She treats both sides with respect and I HIGHLY recommend her.
Recommend Dr. Dana Matthews


Board Certification(s)
Pediatric Hematology-Oncology
Medical/Professional School
University of Washington School of Medicine, Seattle
Clinical Interests

Anemia, hemostasis, thrombosis, and autoimmune cytopenias

Research Description

My research interests include risk-based optimization of the treatment of pediatric thrombosis, and clinical outcomes in patients with hemophilia. In particular, I am participating in projects including an effort to characterize immune responses to factor VIII that result in inhibiting antibodies that significantly complicate the management of hemophilia A, and a prospective study of the development of inhibitors in young patients with hemophilia.

Additionally, I am interested in improving the outcome for pediatric patients with thrombosis by developing clinical trials for subgroups of patients with thrombosis.

Research Focus Area

Blood Disorders

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
SEATTLE MAGAZINE TOP DOCTOR - 2014Seattle Magazine 2014
SEATTLE'S TOP DOCTOR - 2014Seattle Metropolitan Magazine 2014
Seattle Magazine Top Doctor - 2013Seattle Magazine 2013
Seattle's Top DocSeattle Met Magazine 2013
Seattle Magazine Top Doctor - 2012Seattle Magazine Top Doctor - 2012Seattle Magazine 2012
U.S. News Top DoctorU.S. News and World Report 2012
"Guide to America's Top Pediatricians"Consumer's Research Council of America 2009
Scholar in Clinical ResearchLeukemia and Lymphoma Society 1999 - 2003
Trustee, then Medical AdvisorLeukemia Society of America, Washington/Alaska Chapter 1995 - 2003
Trustee, then Medical AdvisorLeukemia Society of America, Washington/Alaska Chapter 1995 - 2003
Special FellowLeukemia Society of America 1992
Fellow,Leukemia Society of America 1987
Alpha Omega AlphaUniversity of Washington, School of Medicine, Seattle, Washington 1981
Phi Beta KappaUniversity of Washington, Seattle, Washington 1977


Inherited disorders of platelet function
Pediatr Clin N Am , 2013: 601475
Sequence-modified factor VIII variants having reduced immunogenicity
American Society of Hematology annual meeting , Dec. 8, 2012 - Dec. 11, 2012
Antithrombin concentrate use in pediatric extracorporeal membrane oxygenation: a retrospective cohort study.
American Society of Hematology Annual Meeting , Dec. 8, 2012 - Dec. 11, 2012
T cells from mild and severe hemophilia A inhibitor subjects recognized the same HLA-restricted epitope in factor VIII
National Hemophilia Foundation Annual Meeting , Nov. 8, 2012 - Nov. 10, 2012
Erythrocyte disorders in infancy
Averys Diseases of the Newborn , 2012: 91080-1107
Determination of anti-factor VIIII antibody titers, isotypes and Epitopes by SPR Analysis of Human Plasma.
American Society of Hematology Annual Meeting , Dec. 9, 2011 - Dec. 13, 2011
Fanconi anemia-like presentation in an infant with constitutional deletion of 21q including the RUNX1 gene
Am J Med Genet , 2011: 155A(7)1673-9
Allogeneic hematopoietic cell transplantation after conditioning with 131Ianti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Blood , 2010: 1145444-5453
Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia
Cancer Res , 2009: 69185-192
Inherited coagulopathic states as a risk factor for complications in pediatric spine patients.
International Meeting on Advanced Spine Techniques , July 8, 2008 - July 11, 2008
The Brighton Collaboration Thrombocytopenia Working Group. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
Vaccine , 2007: 255717-24
Consultative Hematology
American Society of Hematology Self-Assessment Program , 2007: 3466-499
Inferior Vena Cava thrombosis causing acute cauda equina syndrome: A case report.
J Neurosurgery , 2006: 104(1 suppl)46-9
131I-Anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
Blood , 2006: 1072184-91
Biodistribution of yttrium-90 [90Y] labeled anti-CD45 antibody in a nonhuman primate model
Clinical Cancer Research , 2005: 11787-794
Prevention of sensitization to D+ RBCs using RBC exchange and IV Rh immune globulin.
Transfusion , 2004: 441720-23
Radioimmunotherapy and hematopoietic cell transplantation. In: Thomas Hematopoietic Cell Transplantation
Thomas Hematopoietic Cell Transplantation , 2004: 3198-208
Monoclonal antibodies as anti-leukemia and anti-lymphoma drugs. In: Clinical Bone Marrow and Blood Stem Cell Transplantation
Clinical Bone Marrow and Blood Stem Cell Transplantation , 2004: 3705-1715
Conditionally cleavable radioimmunoconjugates: A novel approach for the release of radioisotopes from radioimmunoconjugates
Bioconjug Chem , 2003: 14927-33
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: a multivariable cohort analysis
Blood , 2003: 1022351-7
A comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
Blood , 2003: 1012340-2348
Therapy of acute leukemia with monoclonal antibodies and immunoconjugates.
Treatment of Acute Leukemia: New Directions for Clinical Research , 2003: 485-493
Use of radiolabeled antibodies in the treatment of childhood acute leukemia.
Pediatr Transplant , 2003: 7(Suppl 3)89-94
Rituximab in the very young: benefits in AIHA, at what risk? Invited "Inside Blood" capsule summary
Blood , 2003: 1013761
High dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
Blood , 2002: 993158-3162
Antibody-based therapy of human leukemia
Curr Opin Hematol , 2002: 9316-321
The use of radioimmunoconjugates in stem cell transplantation.
Bone Marrow Transplantation , 2002: 29807-816
Immunosuppressive Effects of 131I-anti-CD45 Antibody in Unsensitized and Donor-Antigen Presensitized H2-Matched, Minor Antigen Mismatched Murine Transplant Models.
Cancer Research , 2001: 615126-5131
Antibody-Targeted Therapy Of AML: An Update. In: Autologous Marrow and Blood Transplantation: Proceedings of the Tenth International Symposium.
Autologous Marrow and Blood Transplantation: Proceedings of the Tenth International Symposium , 2001: 229-242
Monoclonal antibodies in acute leukemia
New Frontiers in Cancer Therapy: Monoclonal antibody therapy of hematologic malignancies , 2001: 219-236
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B cell lymphomas.
Blood , 2000: 962934-2942
Novel preparative regimens I: Tagged antibodies
Handbook of Bone Marrow Transplantation , 2000: 65-94
Radioimmunotherapy in relapsed acute myeloid leukemia. Biologic Therapy of Leukemia:
Acute Leukemia , 2000: 15-9
Current uses of monoclonal antibodies in the treatment of acute leukemia.
Semin Oncol , 2000: 27Semin Oncol
The clinical impact of increased sensitivity PT and aPTT coagulation assays.
Amer. J. Clin. Pathol , 1999: 112225-32
The use of monoclonal antibodies in the treatment of AML
Hematology , 1999: 1999138-142
Monoclonal antibodies in the treatment of acute leukemia
Haematologica , 1999: 84(Suppl 1)
Follow-up of relapsed B-cell lymphoma patients treated with Iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
J Clin Oncol , 1998: 163270-3278
Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome
Leukemia , 1998: 12(Suppl 1)S22-S36
The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies
Winter JN: Blood Stem Cell Transplantation , 1997: 121-139
Barriers to bone marrow transplantation for sickle cell anemia.
Biology of Blood and Bone Marrow Transplant , 1996: 2100-104
Bone marrow transplantation for sickle cell disease: a multicenter collaborative investigation.
New Engl J Med , 1996: 334369-76
Allogeneic marrow transplantation for myelodysplastic synodrome with advanced disease morphology: a Phase II study of busulfan, cyclophosphamide and total body irradiation and analysis of prognostic factors
J Clin Oncol , 1996: 14200-6
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
Cancer Res , 1996: 562123-2129
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors
Blood , 1996: 8751-58
The role of radioimmunotherapy in bone marrow transplantation
Curr Opin Hematl , 1996: 3438--45
Unrelated donor marrow transplantation in children.
Blood , 1995: 863247-3256
Neurologic complications following allogeneic marrow transplantation for sickle cell anemia.
Blood , 1995: 85879-884
Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation
Blood , 1995: 851122-1131
Targeted therapy for hematologic malignancies: has its promise been realized?
Curr Opin Hematol , 1995: 2235-239
The application of radioimmunotherapy to marrow transplantation.
Bone Marrow Transplantation , 1995: 15(Supplement 1)S188-S192
Post therapy imaging in high dose I-131 radioimmunotherapy patients
Med Phys , 1994: 211157-1162
Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support.
NEJM , 1993: 3291219-1224
High dose radioimmunotherapy of lymphoma
Cancer Treatment and Research , 1993: 6813-22
Bone marrow transplantation for hemoglobinopathy and sickle cell disease.
Recent Advances in Hematology , 1993: 7119-134
Use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.
Transplantation , 1992: 54829 - 833
Tumor localization of radiolabeled anti-myeloid antibodies in a human acute leukemia xenograft model
Cancer Research , 1992: 5289-94
Therapy of Hematologic Malignancies Using Radioimmunotherapy (RAIT)
Cambridge Medical Reviews: Haematology-Oncology , 1992: 15-27
Monoclonal antibodies in the study and therapy of hematopoietic cancers.
Current Opinion in Immunology , 1992: 4641-646
Is there a better way to deliver total body irradiation?
Bone Marrow Transplantation , 1992: 10(Suppl 1)77-81
Treatment of leukemia and lymphoma using antibody labeled with high doses of 131I.
Antib. Immunoconjug. Radiopharm , 1991: 4771-776
Radiolabeled anti-CD45 monoclonal antibodies target hematolymphoid tissue in murine and macaque models
Antib. Immunoconjug. Radiopharm , 1991: 4713-719
Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I.
Cancer Research , 1991: 515921-5928
Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque
Blood , 1991: 781864-1874
Radiolabeled antibody therapy of human B cell lymphomas: Advances in Experimental Biology and Medicine.
Immunobiology of Proteins and Peptides VI , 1991: 91-96
Chronic graft-versus-host disease and the late complications of bone marrow transplantation.
Seminars in Hematology , 1991: 28250-259
Chronic graft-versus-host disease: recent advances in diagnosis and treatment
Bone Marrow Transplantation: Current Controversies , 1989: 91511-522,
Homing receptors and metastasis
Advances in Cancer Research , 1988: 51361-390
Chronic graft-versus-host disease: pathogenesis, diagnosis, treatment and prognostic factors.
Recent Advances and Future Directions in Bone Marrow Transplantation. Experimental Hematology Today,Recent Advances and Future Directions in Bone Marrow Transplantation , 1987: 150-157

Research Funding

Grant TitleGrantorAmountAward Date
Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in HemophiliaNational Institutes of HealthSept. 30, 2010

Primary Office

Seattle Children's
MB.8.501 - Hematology-Oncology
4800 Sand Point Way NE
Seattle, WA 98105

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options